{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T09:37:44Z","timestamp":1758706664353,"version":"3.40.3"},"publisher-location":"Cham","reference-count":57,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783319131498"},{"type":"electronic","value":"9783319131504"}],"license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/978-3-319-13150-4_10","type":"book-chapter","created":{"date-parts":[[2015,2,6]],"date-time":"2015-02-06T02:05:53Z","timestamp":1423188353000},"page":"251-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Treatment Strategies in Mantle Cell Lymphoma"],"prefix":"10.1007","author":[{"given":"Kami","family":"Maddocks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,2,7]]},"reference":[{"key":"10_CR1","first-page":"229","volume-title":"WHO classification of tumors of hematopoietic and lymphoid tissues","author":"S Swerdlow","year":"2008","unstructured":"Swerdlow S, Campo E, Harris N et al (2008) WHO classification of tumors of hematopoietic and lymphoid tissues. World Health Organization, Lyon, pp 229\u2013232"},{"issue":"7","key":"10_CR2","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1023\/A:1008265532487","volume":"9","author":"JR Anderson","year":"1998","unstructured":"Anderson JR, Armitage JO et al (1998) Epidemiology of the non-Hodgkin\u2019s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin\u2019s lymphoma classification project. Ann Oncol 9(7):717\u2013720","journal-title":"Ann Oncol"},{"issue":"4","key":"10_CR3","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/cncr.23608","volume":"113","author":"Y Zhou","year":"2008","unstructured":"Zhou Y, Wang H et al (2008) Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancerb 113(4):791\u2013798","journal-title":"Cancerb"},{"key":"10_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329:987\u2013994","journal-title":"N Engl J Med"},{"key":"10_CR5","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","volume":"111","author":"E Hoster","year":"2008","unstructured":"Hoster E, Dreyling M, Klapper W et al (2008) A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood 111:558\u2013565","journal-title":"Blood"},{"issue":"8","key":"10_CR6","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","volume":"87","author":"L Hernandez","year":"1996","unstructured":"Hernandez L, Fest T, Cazorla M, Teruya-Feldstein J, Bosch F, Peinado MA et al (1996) p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 87(8):3351\u20133359","journal-title":"Blood"},{"issue":"10","key":"10_CR7","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","volume":"87","author":"TC Greiner","year":"1996","unstructured":"Greiner TC, Moynihan MJ, Chan WC, Lytle DM, Pedersen A, Anderson JR et al (1996) p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87(10):4302\u20134310","journal-title":"Blood"},{"issue":"2","key":"10_CR8","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/S0002-9440(10)63140-9","volume":"164","author":"A Martinez","year":"2004","unstructured":"Martinez A, Bellosillo B, Bosch F, Ferrer A, Marce S, Villamor N et al (2004) Nuclear surviving expression in mantle cell lymphoma is associated with cell proliferation and survival. Am J Pathol 164(2):501\u2013510","journal-title":"Am J Pathol"},{"issue":"1","key":"10_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0609.2002.01677.x","volume":"69","author":"R Raty","year":"2002","unstructured":"Raty R, Franssila K, Joensuu H, Teerenhovi L, Elonen E (2002) Ki-67 expression level, histological subtype, and the International Prognostic Index as outcome predictors in mantle cell lymphoma. Eur J Haematol 69(1):11\u201320","journal-title":"Eur J Haematol"},{"key":"10_CR10","doi-asserted-by":"crossref","unstructured":"Cohen JB, Ruppert AS, Heerema NA et al (2012) Complex Karyotype (CK) is associated with a shortened progression-free survival (PFS) in patients with newly diagnosed mantle cell lymphoma. Blood A:2691","DOI":"10.1182\/blood.V120.21.2691.2691"},{"issue":"1","key":"10_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/gcc.22123","volume":"53","author":"C Sarkozy","year":"2014","unstructured":"Sarkozy C, Terr\u00e9 C, Jardin F et al (2014) Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromo Cancer 53(1):106\u2013116. doi:10.1002\/gcc.22123","journal-title":"Genes Chromo Cancer"},{"key":"10_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1053\/S0046-8177(03)00410-6","volume":"34","author":"L Nodit","year":"2003","unstructured":"Nodit L, Bahler D, Jacobs S et al (2003) Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes. Hum Pathol 34:1030\u20131034","journal-title":"Hum Pathol"},{"issue":"20","key":"10_CR13","doi-asserted-by":"publisher","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, Clot G, Royo C et al (2012) Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX22 expression have distinct biologic and clinical features. Cancer Res 72(20):5307\u20135316","journal-title":"Cancer Res"},{"key":"10_CR14","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1093\/annonc\/mdg414","volume":"14","author":"HA Leitch","year":"2003","unstructured":"Leitch HA, GAscoyne RD, Chhanabhai M et al (2003) Limited-stage mantle-cell lymphoma. Ann Oncol 14:1555\u20131561","journal-title":"Ann Oncol"},{"key":"10_CR15","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","volume":"27","author":"P Martin","year":"2009","unstructured":"Martin P, Chadburn A, Christos P et al (2009) Outcome of deferred initial therapy in mantle cell lymphoma. J Clin Oncol 27:1209\u20131213","journal-title":"J Clin Oncol"},{"key":"10_CR16","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","volume":"23","author":"J Romaguera","year":"2005","unstructured":"Romaguera J, Fayad L, Rodriquez MA et al (2005) High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013\u20137023","journal-title":"J Clin Oncol"},{"key":"10_CR17","doi-asserted-by":"crossref","first-page":"A387","DOI":"10.1182\/blood.V110.11.387.387","volume":"110","author":"EM Epner","year":"2007","unstructured":"Epner EM, Unger J, Miller T, Romzsa L, Spier C, Leblanc M, Fisher R (2007) A multi-center trial of hyperCVAD\u00a0+\u00a0rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 110:A387","journal-title":"Blood"},{"key":"10_CR18","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","volume":"24","author":"SH Bernstein","year":"2013","unstructured":"Bernstein SH, Epner E, Unger JM et al (2013) A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 24:1587\u20131593","journal-title":"Ann Oncol"},{"key":"10_CR19","doi-asserted-by":"crossref","unstructured":"Merli F, Luminari S, Ilariucci F, et al (2012) Rituximab plus hyper CVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. A multicenter trial from GISL. Brit J Haematol 156:346\u2013353","DOI":"10.1111\/j.1365-2141.2011.08958.x"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"M Dreyling","year":"2005","unstructured":"Dreyling M, Lenz G, Hoster E et al (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progress-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL network. Blood 105:2677\u20132684","journal-title":"Blood"},{"key":"10_CR21","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","volume":"27","author":"LE Damon","year":"2009","unstructured":"Damon LE, Johnson JL, Niedzwiecki D et al (2009) Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 27:6101\u20136108","journal-title":"J Clin Oncol"},{"key":"10_CR22","unstructured":"Kaplan LD, Jung S, Bartelet N et al (2013) Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB 50403. Hematol Oncol 31:A89"},{"key":"10_CR23","doi-asserted-by":"crossref","unstructured":"Geisler CH, Kolstad A, Laurell A, Andersen NS, Pedersen LB, Jerkeman M, Eriksson M, Nordstr\u00f6m\u00a0M, Kimby E, Boesen AM, Kuittinen O, Lauritzsen GF, Nilsson-Ehle H, Ralfkiaer E, Akerman M, Ehinger M, Sundstr\u00f6m C, Langholm R, Delabie J, Karjalainen-Lindsberg ML, Brown P, Elonen E, Nordic Lymphoma Group (2008) Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase II multicenter study by the Nordic Lymphoma Group. Blood 112:2687\u20132693","DOI":"10.1182\/blood-2008-03-147025"},{"key":"10_CR24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler CH, Kolstad A, Laurell A et al (2012) Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+\u00a0autologous stem- cell support: still very long survival but late relapses do occur. Br J Haematol 158:355\u2013362","journal-title":"Br J Haematol"},{"key":"10_CR25","doi-asserted-by":"crossref","unstructured":"Andersen NS, Pedersen L, Elonen E et al. (2003) Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 71:73\u201380","DOI":"10.1034\/j.1600-0609.2003.00093.x"},{"key":"10_CR26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","volume":"121","author":"R Delarue","year":"2013","unstructured":"Delarue R, Haioun C, Ribrag V et al (2013) CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a phase II study from the GELA. Blood 121:48\u201353","journal-title":"Blood"},{"key":"10_CR27","doi-asserted-by":"crossref","unstructured":"Pott C, Hoster E, Beldjord K, et al (2010) R-CHOP\/R-DHAP compared to R-CHOP induction followed by high dose therapy with autologous stem cell transplantation induces higher rates of molecular remission in MCL: results of the MCL younger intergroup trial of the European MCL Network [abstract]. Blood 116:965","DOI":"10.1182\/blood.V116.21.965.965"},{"key":"10_CR28","doi-asserted-by":"crossref","unstructured":"Budde LE, Guthric KA, Til BG et al (2011) Mantle Cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29:3023","DOI":"10.1200\/JCO.2010.33.7055"},{"issue":"4","key":"10_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.3324\/haematol.2011.050203","volume":"97","author":"H Liu","year":"2012","unstructured":"Liu H, Johnson JL, Loval G et al (2012) Detection of minimal residual disease following induction chemoimmunotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909. Hematologica 97(4):579\u2013585","journal-title":"Hematologica"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","volume":"115","author":"C Pott","year":"2010","unstructured":"Pott C, Hoster E, Delfau-Larue MH et al (2010) Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 115:3215\u20133223","journal-title":"Blood"},{"issue":"1","key":"10_CR31","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1023\/A:1008309405678","volume":"11","author":"JM Foran","year":"2000","unstructured":"Foran JM, Cunningham D, Coiffier B (2000) Treatment of mantle-cell lymphoma with rituximab (chimeric anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 11(1):117\u2013121","journal-title":"Ann Oncol"},{"issue":"2","key":"10_CR32","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran JM, Rohatiner AZ, Cunningham D et al (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18(2):317\u2013324","journal-title":"J Clin Oncol"},{"issue":"4","key":"10_CR33","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","volume":"23","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Schmitz SF, Cogliatti S et al (2005) Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 23(4):705\u2013711","journal-title":"J Clin Oncol"},{"key":"10_CR34","doi-asserted-by":"crossref","unstructured":"Kluin-Nelemans JC, Hoster E, Walewski J, et al (2011) R-CHOP versus R-FC followed by maintenance with Rituximab versus interferon-Alfa: outcome of the first randomized trial for elderly patients with mantle cell lymphoma [abstract]. Blood 118:439","DOI":"10.1182\/blood.V118.21.439.439"},{"key":"10_CR35","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","volume":"381","author":"MJ Rummel","year":"2013","unstructured":"Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL): an open-label, multicentre, randomized, phase 3 non-inferiority trial. Lancet 381:1203\u20131210","journal-title":"Lancet"},{"key":"10_CR36","doi-asserted-by":"crossref","unstructured":"Flinn IW, van der Jagt R, Kahl BS et al (2014) Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study. Blood, Epub","DOI":"10.1182\/blood-2013-11-531327"},{"key":"10_CR37","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/cncr.23537","volume":"113","author":"DJ Inward","year":"2008","unstructured":"Inward DJ, Fishkin PA, Hillman DW et al (2008) Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone or 2-CDA and rituximab in the North Central Cancer Treatment Group. Cancer 113:108\u2013116","journal-title":"Cancer"},{"key":"10_CR38","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH, Buggy JJ, Sharman JP et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol 31:88\u201394","journal-title":"J Clin Oncol"},{"key":"10_CR39","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507","DOI":"10.1056\/NEJMoa1306220"},{"key":"10_CR40","doi-asserted-by":"crossref","unstructured":"Budde LE, Guthric KA, Til BG et al (2011) Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. J Clin Oncol 29:3023","DOI":"10.1200\/JCO.2010.33.7055"},{"key":"10_CR41","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","volume":"145","author":"TM Habermann","year":"2009","unstructured":"Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, Wride K, Ervin-Haynes A, Takeshita K, Pietronigro D, Zeldis JB, Tuscano JM (2009) Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle-cell lymphoma. Brit J Haem 145:344\u2013349","journal-title":"Brit J Haem"},{"key":"10_CR42","doi-asserted-by":"crossref","unstructured":"Reeder CB, Witzig TE, Zinzani PL et al (2009) Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results from an international study (NHL-003) [abstract]. J Clin Oncol 27:8569","DOI":"10.1200\/jco.2009.27.15_suppl.8569"},{"key":"10_CR43","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Vose JM, Czuczman MS, et al (2012) Phase II multicenter study of the safety and efficacy of single-agent lenalidomide in subjects with relapsed\/refractory mantle cell lymphoma: long-term follow-up analysis of the nhl-003 study [abstract]. Blood 120:2738","DOI":"10.1182\/blood.V120.21.2738.2738"},{"key":"10_CR44","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","volume":"13","author":"M Wang","year":"2012","unstructured":"Wang M, Fayad L, Wagner-Bartak N et al (2012) Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial. Lancet Oncol 13:716\u2013723","journal-title":"Lancet Oncol"},{"key":"10_CR45","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS et al (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867\u20134874","journal-title":"J Clin Oncol"},{"key":"10_CR46","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1093\/annonc\/mdn656","volume":"20","author":"A Goy","year":"2009","unstructured":"Goy A, Bernstein SH, Kahl BS et al (2009) Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analysis of the multicenter phase 2 PINNACLE study. Ann Oncol 20:520\u2013525","journal-title":"Ann Oncol"},{"key":"10_CR47","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","volume":"23","author":"MJ Rummel","year":"2005","unstructured":"Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin\u2019s lymphoma. J Clin Oncol 23:3383\u20133389","journal-title":"J Clin Oncol"},{"key":"10_CR48","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2008.17.0001","volume":"26","author":"KS Robinson","year":"2008","unstructured":"Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD (2008) Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin\u2019s lymphoma. J Clin Oncol 26:4473\u20134479","journal-title":"J Clin Oncol"},{"key":"10_CR49","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","volume":"117","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW, Vose JM, Kelly JL et al (2011) The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell lymphoma. Blood 117:2807\u20132812","journal-title":"Blood"},{"issue":"6","key":"10_CR50","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1080\/10428190801923725","volume":"49","author":"BG Till","year":"2008","unstructured":"Till BG, Gooley TA, Crawford N et al (2008) Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma. Leuk Lymphoma 49(6):1062\u20131073","journal-title":"Leuk Lymphoma"},{"key":"10_CR51","first-page":"444","volume":"113","author":"CS Tam","year":"2009","unstructured":"Tam CS, Bassett R, Ledesma C et al (2009) Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 113:444\u20134152","journal-title":"Blood"},{"key":"10_CR52","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","volume":"21","author":"IF Khouri","year":"2003","unstructured":"Khouri IF, Lee MS, Saliba RM et al (2003) Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma. J Clin Oncol 21:4407\u20134412","journal-title":"J Clin Oncol"},{"key":"10_CR53","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","volume":"104","author":"MB Mari","year":"2004","unstructured":"Mari MB, Sandmaier BM, Storer BE et al (2004) Allogeneic hematopoietic cell transplantation after fludarabine and 2\u00a0Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 104:3535\u20133542","journal-title":"Blood"},{"key":"10_CR54","doi-asserted-by":"crossref","unstructured":"Ruan J, Martin P, Shah B et al (2013) Combination biologic therapy without chemotherapy as initial treatment for mantel cell lymphoma: multi-center phase II study of lenalidomide plus rituximab. Blood 21:247","DOI":"10.1182\/blood.V122.21.247.247"},{"key":"10_CR55","doi-asserted-by":"crossref","unstructured":"Blum K (2012) A phase i trial of the Bruton\u2019s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed\/refractory non-Hodgkin\u2019s lymphoma (NHL). Blood, p 1643","DOI":"10.1182\/blood.V120.21.1643.1643"},{"key":"10_CR56","unstructured":"Kahl BS, Spurgeon, SE, Furman RR et al (2013) Results of a phase I study of idelalisb, a PI3\u03ba\u03b4 inhibitor with relapsed or refractory mantle cell lymphoma (MCL). Blood Abstract85"},{"key":"10_CR57","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1182\/blood-2012-02-414060","volume":"120","author":"MS Davids","year":"2012","unstructured":"Davids MS, Roberts AW, Anderson MA et al (2012) The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-hodgkin lymphoma: interim results of a phase I study [abstract]. Blood 120:404","journal-title":"Blood"}],"container-title":["Cancer Treatment and Research","Non-Hodgkin Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-319-13150-4_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T05:20:43Z","timestamp":1674192043000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-319-13150-4_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783319131498","9783319131504"],"references-count":57,"URL":"https:\/\/doi.org\/10.1007\/978-3-319-13150-4_10","relation":{},"ISSN":["0927-3042"],"issn-type":[{"type":"print","value":"0927-3042"}],"subject":[],"published":{"date-parts":[[2015]]},"assertion":[{"value":"7 February 2015","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}